• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

胰十二指肠切除术联合血管重建治疗老年可切除胰腺癌的长期疗效。

Long-Term Effect of Pancreaticoduodenectomy Combined with Revascularization for Resectable Pancreatic Carcinoma in Elderly Patients.

机构信息

Department of Hepatopancreatobiliary Surgery, Chongqing General Hospital, Chongqing, China (mainland).

Department of Surgery, Hospital of People's Liberation Army Unit 63820, Mianyang, Sichuan, China (mainland).

出版信息

Med Sci Monit. 2022 Nov 21;28:e938443. doi: 10.12659/MSM.938443.

DOI:10.12659/MSM.938443
PMID:36404606
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9695170/
Abstract

BACKGROUND Pancreaticoduodenectomy combined with revascularization (PDR) is the main surgical procedure for resectable pancreatic ductal adenocarcinoma (PDAC) with venous system invasion, but this procedure is discouraged in elderly patients because of physical complexity. Our aim was to explore the differences of perioperative and survival in patients of different ages who underwent PDR. MATERIAL AND METHODS We reviewed data from PDAC patients undergoing PDR from 2007 to 2018. Patients were subdivided into 3 groups according to age: <60 years, 60-70 years, and ≥70 years. Postoperative complications and long-term survival were compared among the 3 groups. RESULTS From 626 patients, 185 had en bloc venous resection who underwent PDR (103, 55, and 27 patients from young to elderly). Increasing age was linked to a higher prevalence of ICU management (P=0.035) and more serious complications (grade ≥III, P=0.043); overall mortality was 8.1% and did not significantly differ among age-matched groups. Further, there was no difference in overall survival (OS) or progression-free survival (PFS) based on age (<60, 60-70, ≥70, median OS were 9.7, 8.4 vs 9.1 months, respectively, P=0.787; median PFS were 6.9, 6.1 vs 8.4 months, respectively, P=0.603). However, patients <60 years whose tumors invaded the superior mesenteric vascular had better survival outcomes when compared with the other 2 groups (11.5 vs 8.4, 9.1 months, P=0.049). CONCLUSIONS The results show that age should not be considered an absolute contraindication for PDR, as elderly patients can achieve the same surgical efficacy and long-term survival prognosis.

摘要

背景

胰十二指肠切除术联合血管重建(PDR)是可切除的胰腺导管腺癌(PDAC)伴静脉系统侵犯的主要手术方法,但由于手术复杂性,该手术在老年患者中不被鼓励。我们的目的是探讨不同年龄接受 PDR 的患者围手术期和生存差异。

材料和方法

我们回顾了 2007 年至 2018 年期间接受 PDR 的 PDAC 患者的数据。根据年龄将患者分为 3 组:<60 岁、60-70 岁和≥70 岁。比较 3 组患者的术后并发症和长期生存情况。

结果

从 626 例患者中,有 185 例行整块静脉切除的 PDR 手术(年轻至老年患者分别为 103、55 和 27 例)。年龄增长与 ICU 管理(P=0.035)和更严重的并发症(≥III 级,P=0.043)的发生率较高相关;总死亡率为 8.1%,在年龄匹配组之间无显著差异。此外,根据年龄,总生存率(OS)或无进展生存率(PFS)没有差异(<60、60-70、≥70 岁,中位 OS 分别为 9.7、8.4 与 9.1 个月,P=0.787;中位 PFS 分别为 6.9、6.1 与 8.4 个月,P=0.603)。然而,与其他 2 组相比,<60 岁且肿瘤侵犯肠系膜上血管的患者生存结果更好(11.5 与 8.4、9.1 个月,P=0.049)。

结论

结果表明,年龄不应作为 PDR 的绝对禁忌证,因为老年患者可以获得相同的手术疗效和长期生存预后。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee55/9695170/7d2287151807/medscimonit-28-e938443-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee55/9695170/7d2287151807/medscimonit-28-e938443-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee55/9695170/7d2287151807/medscimonit-28-e938443-g001.jpg

相似文献

1
Long-Term Effect of Pancreaticoduodenectomy Combined with Revascularization for Resectable Pancreatic Carcinoma in Elderly Patients.胰十二指肠切除术联合血管重建治疗老年可切除胰腺癌的长期疗效。
Med Sci Monit. 2022 Nov 21;28:e938443. doi: 10.12659/MSM.938443.
2
Long-term outcomes following en bloc resection for pancreatic ductal adenocarcinoma of the head with portomesenteric venous invasion.胰头导管腺癌伴门静脉肠系膜静脉侵犯整块切除术的长期结果。
Asian J Surg. 2021 Jan;44(1):313-320. doi: 10.1016/j.asjsur.2020.07.021. Epub 2020 Sep 21.
3
The impact of extent of pancreatic and venous resection on survival for patients with pancreatic cancer.胰腺和静脉切除范围对胰腺癌患者生存的影响。
Hepatobiliary Pancreat Dis Int. 2019 Aug;18(4):389-394. doi: 10.1016/j.hbpd.2019.06.004. Epub 2019 Jun 10.
4
Rationale for en bloc vein resection in the treatment of pancreatic adenocarcinoma adherent to the superior mesenteric-portal vein confluence. Pancreatic Tumor Study Group.整块切除静脉在治疗粘连于肠系膜上静脉-门静脉汇合处的胰腺腺癌中的理论依据。胰腺肿瘤研究小组。
Ann Surg. 1996 Feb;223(2):154-62. doi: 10.1097/00000658-199602000-00007.
5
Significance of Portal Vein Invasion and Extent of Invasion in Patients Undergoing Pancreatoduodenectomy for Pancreatic Adenocarcinoma.门静脉侵犯及侵犯范围在接受胰十二指肠切除术的胰腺腺癌患者中的意义
J Gastrointest Surg. 2016 Mar;20(3):479-87; discussion 487. doi: 10.1007/s11605-015-3005-y. Epub 2016 Jan 14.
6
Postoperative morbidity and long-term survival after pancreaticoduodenectomy with superior mesenterico-portal vein resection.肠系膜上静脉-门静脉切除的胰十二指肠切除术后的术后发病率和长期生存率。
J Gastrointest Surg. 2006 Sep-Oct;10(8):1106-15. doi: 10.1016/j.gassur.2006.04.002.
7
Outcomes of vascular resection in pancreaticoduodenectomy: single-surgeon experience.胰十二指肠切除术中血管切除的结果:单术者经验
Am Surg. 2013 Oct;79(10):1064-7.
8
[En bloc vein resection in the treatment of pancreatic tumors adherent to the superior mesenteric-portal vein confluence].整块静脉切除治疗累及肠系膜上静脉-门静脉汇合处的胰腺肿瘤
Zhonghua Wai Ke Za Zhi. 1997 Mar;35(3):144-6.
9
Superior mesenteric vein/portal vein contact in preoperative imaging indicates biological malignancy in anatomically resectable pancreatic cancer.术前影像学检查显示肠系膜上静脉/门静脉接触提示可解剖切除的胰腺癌存在生物学恶性特征。
Surg Oncol. 2023 Dec;51:101998. doi: 10.1016/j.suronc.2023.101998. Epub 2023 Sep 20.
10
Survival following pancreaticoduodenectomy with resection of the superior mesenteric-portal vein confluence for adenocarcinoma of the pancreatic head.胰十二指肠切除术联合切除肠系膜上静脉-门静脉汇合部治疗胰头腺癌后的生存情况。
Br J Surg. 1998 May;85(5):611-7. doi: 10.1046/j.1365-2168.1998.00641.x.

本文引用的文献

1
Cancer incidence and mortality in China, 2016.2016年中国癌症的发病率和死亡率
J Natl Cancer Cent. 2022 Feb 27;2(1):1-9. doi: 10.1016/j.jncc.2022.02.002. eCollection 2022 Mar.
2
Pancreatic Cancer: Pathogenesis, Screening, Diagnosis, and Treatment.胰腺癌:发病机制、筛查、诊断和治疗。
Gastroenterology. 2022 Aug;163(2):386-402.e1. doi: 10.1053/j.gastro.2022.03.056. Epub 2022 Apr 7.
3
Advances in the epidemiology of pancreatic cancer: Trends, risk factors, screening, and prognosis.胰腺癌流行病学研究进展:趋势、风险因素、筛查和预后。
Cancer Lett. 2021 Nov 1;520:1-11. doi: 10.1016/j.canlet.2021.06.027. Epub 2021 Jun 30.
4
Curing pancreatic cancer.治愈胰腺癌。
Semin Cancer Biol. 2021 Nov;76:232-246. doi: 10.1016/j.semcancer.2021.05.030. Epub 2021 May 29.
5
Preoperative Computed Tomography Imaging of the Pancreas Identifying Predictive Factors for the Progression of Grade A, or Biochemical Leak, to Grade B Postoperative Pancreatic Fistula Following Pancreaticoduodenectomy: A Retrospective Study.术前胰腺计算机断层成像识别胰十二指肠切除术后 Grade A(或生化漏)进展为 Grade B 术后胰瘘的预测因素:一项回顾性研究。
Med Sci Monit. 2021 Feb 25;27:e928489. doi: 10.12659/MSM.928489.
6
Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment.新辅助 FOLFIRINOX 治疗后行切除术的胰腺癌患者辅助化疗的评价。
JAMA Oncol. 2020 Nov 1;6(11):1733-1740. doi: 10.1001/jamaoncol.2020.3537.
7
The role of older age and obesity in minimally invasive and open pancreatic surgery: A systematic review and meta-analysis.老年和肥胖在微创和开放胰腺手术中的作用:系统评价和荟萃分析。
Pancreatology. 2020 Sep;20(6):1234-1242. doi: 10.1016/j.pan.2020.06.013. Epub 2020 Jul 14.
8
The efficacy and toxicity of chemotherapy in the elderly with advanced pancreatic cancer.老年晚期胰腺癌患者化疗的疗效和毒性。
Pancreatology. 2020 Jan;20(1):95-100. doi: 10.1016/j.pan.2019.11.012. Epub 2019 Nov 23.
9
The Impact of Immunonutritional and Physical Status on Surgical Outcome After Pancreaticoduodenectomy in Elderly Patients.免疫营养和身体状况对老年患者胰十二指肠切除术后手术结果的影响。
Anticancer Res. 2019 Nov;39(11):6347-6353. doi: 10.21873/anticanres.13846.
10
Pancreatoduodenectomy with portal vein resection favors the survival time of patients with pancreatic ductal adenocarcinoma: A propensity score matching analysis.门静脉切除的胰十二指肠切除术有利于胰腺导管腺癌患者的生存时间:一项倾向评分匹配分析。
Oncol Lett. 2019 Nov;18(5):4563-4572. doi: 10.3892/ol.2019.10822. Epub 2019 Sep 6.